===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Interferon Sciences, Inc.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value
- -------------------------------------------------------------------------------
(Title of Class of Securities)
458903101
- -------------------------------------------------------------------------------
(CUSIP Number)
David Jacobs, Esq.
American National Red Cross
8111 Gatehouse Road
Falls Church, VA 22042
703-807-5249
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Persons Authorized to
Receive Notices and Communications)
December 7, 1998
- -------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ X ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
any subsequent amendment containing information which would alter disclosures
provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
"filed" for the purpose of Section 18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
===============================================================================
<PAGE>
CUSIP No. 458903101 Page 2 of 5
- -------------------------------------------------------------------------------
1) Name of Reporting Person
I.R.S. Identification No. of Above Person (entities only)
American National Red Cross
EIN: 53-0196605
- -------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group: Not applicable
(a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3) SEC Use only
- -------------------------------------------------------------------------------
4) Citizenship or Place of Organization:
Federally chartered (36 U.S.C. ss. 300101)
- -------------------------------------------------------------------------------
Number of Units Beneficially owned by Each Reporting Person with:
5) Sole Voting Power: 300,000
- -------------------------------------------------------------------------------
6) Shared Voting Power: Not applicable.
- -------------------------------------------------------------------------------
7) Sole Dispositive Power: 300,000
- -------------------------------------------------------------------------------
8) Shared Dispositive Power: Not applicable.
- -------------------------------------------------------------------------------
9) Aggregate Amount Beneficially
owned by Each Reporting Person: 300,000
- -------------------------------------------------------------------------------
10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares:
[ ]
- -------------------------------------------------------------------------------
11) Percent of Class Represented by Amount in Row (9): 7.4%
- -------------------------------------------------------------------------------
12) Type of Reporting Person: CO
<PAGE>
CUSIP No. 458903101 Page 3 of 5
- -------------------------------------------------------------------------------
Schedule 13G
------------
Item 1. (a) Name of Issuer:
Interferon Sciences, Inc.
(b) Address of Issuer's Principal Executive Offices:
783 Jersey Avenue
New Brunswick, New Jersey 08901
Item 2. (a) Name of Person Filing:
American National Red Cross
(b) Address of Principal Business Office, or, if none,
Residence:
8111 Gatehouse Road
Falls Church, VA 22042
(c) Citizenship:
Federally chartered, 36 U.S.C. ss. 300101
(d) CUSIP Number:
458903101
Item 3. If this statement is filed pursuant to Rules 13d-1(b) or
13d-2(b), check whether the person filing is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act
(b) [ ] Bank as defined in Section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act
(d) [ ] Investment Company registered under Section 8 of the Investment
Company Act
(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940
(f) [ ] Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act of
1974 or Endowment Fund; see Section 401.13d-1(b)(1)(ii)(F)
<PAGE>
CUSIP No. 458903101 Page 4 of 5
- -------------------------------------------------------------------------------
(g) [ ] Parent Holding Company, in accordance with Section
240.13d-1(b)(1)(ii)(G) (Note: See Item 7)
(h) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(H)
Item 4. Ownership.
Provide the following information regarding the aggregate
number and percentage of the class of securities identified in Item 1.
(a) Amount beneficially owned: 300,000
(b) Percent of class: 7.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or direct the vote: 300,000(1)
(ii) shared power to vote or direct the vote: Not
Applicable.
(iii) sole power to dispose or to direct the
disposition of: 300,000
(iv) shared power to dispose or direct the
disposition of: Not Applicable.
(1) Interferon Sciences, Inc. ("ISI") transferred 300,000 shares of its
common stock to American National Red Cross ("ARC") as partial payment for
product previously supplied to ISI by ARC pursuant to the terms of a supply
agreement dated April 1, 1997 between ARC and ISI. Pursuant to the terms of an
agreement between ARC and ISI, ISI may in the future transfer additional shares
of its common stock to ARC as payment for such product. The number of shares of
ISI common stock that ARC may receive in the future under such agreement cannot
be estimated at the present time. ARC intends to sell the 300,000 shares of ISI
common stock, and any additional shares of ISI common stock it may receive from
ISI in the future, in the open market or otherwise from time to time based on
its assessment of market conditions.
Item 5. Ownership of Five Percent or less of a class:
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following: [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
Not Applicable.
<PAGE>
CUSIP No. 458903101 Page 5 of 5
- -------------------------------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification and Signature.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
AMERICAN NATIONAL RED CROSS
By: /s/ N. M. Conway
----------------
Name: N. M. Conway
Title: Vice President
Date: February 3, 1999
